Information: NIBIO
Elucidation of the Mode of Action of Novel Universal Influenza Vaccine Candidates
Jun. 28, 2023
The National Institutes of Biomedical Innovation, Health and Nutrition (Ibaraki, Osaka, Japan; President: Yusuke Nakamura, "NIBIOHN") and Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announced today that the results of the latest successful study conducted by a joint research group of the NIBIOHN, Sumitomo Pharma, and the National Institute of Infectious Diseases (Shinjuku, Tokyo, Japan; Director-General: Takaji Wakita) to develop "universal influenza vaccines" that provide protection against a broad range of influenza viruses. The group, for the first time, has demonstrated that their novel universal influenza vaccine candidate formulations adjuvanted with "DSP-0546LP", a toll-like receptor 7 (TLR7) agonist, provide a strong protection against heterologous strains (cross-protection), elucidated the mode of action of the formulations, and indicated the significance of the TLR7 adjuvant "DSP-0546LP."
The results of this study were published online in the international academic journal Vaccine on June 15, 2023.
Please click here for the detail.